47.73
0.20%
-0.05
Schlusskurs vom Vortag:
$47.78
Offen:
$47.64
24-Stunden-Volumen:
117.60K
Relative Volume:
0.07
Marktkapitalisierung:
$120.15B
Einnahmen:
$53.04B
Nettoeinkommen (Verlust:
$4.93B
KGV:
15.04
EPS:
3.1735
Netto-Cashflow:
$15.63B
1W Leistung:
-0.28%
1M Leistung:
-11.13%
6M Leistung:
-2.58%
1J Leistung:
+2.44%
Sanofi Adr Stock (SNY) Company Profile
Vergleichen Sie SNY mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
SNY | 47.73 | 120.15B | 53.04B | 4.93B | 15.63B | 3.1735 |
LLY | 745.81 | 693.54B | 40.86B | 8.37B | -2.28B | 5.4193 |
NVO | 102.26 | 465.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
JNJ | 153.22 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
ABBV | 167.96 | 294.70B | 55.53B | 5.12B | 15.62B | 3.65 |
MRK | 97.56 | 248.54B | 63.17B | 12.15B | 14.84B | 1.80 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-07-26 | Bestätigt | Argus | Buy |
2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
2024-01-16 | Fortgesetzt | UBS | Buy |
2023-12-05 | Herabstufung | JP Morgan | Overweight → Neutral |
2023-10-30 | Herabstufung | Stifel | Buy → Hold |
2023-09-06 | Hochstufung | Berenberg | Hold → Buy |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-04-28 | Herabstufung | Deutsche Bank | Hold → Sell |
2023-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
2022-12-13 | Fortgesetzt | Morgan Stanley | Overweight |
2022-08-12 | Hochstufung | Deutsche Bank | Sell → Hold |
2022-08-09 | Herabstufung | UBS | Buy → Neutral |
2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
2021-09-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2021-01-15 | Eingeleitet | Deutsche Bank | Sell |
2020-09-29 | Eingeleitet | Berenberg | Hold |
2020-03-17 | Hochstufung | Barclays | Underweight → Equal Weight |
2020-03-11 | Hochstufung | Goldman | Neutral → Buy |
2020-02-11 | Eingeleitet | SVB Leerink | Mkt Perform |
2020-01-06 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
2019-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2019-09-03 | Eingeleitet | Bernstein | Outperform |
2019-08-14 | Hochstufung | UBS | Neutral → Buy |
2018-12-11 | Hochstufung | Jefferies | Hold → Buy |
2018-11-01 | Hochstufung | Barclays | Underweight → Equal Weight |
2018-10-09 | Eingeleitet | Guggenheim | Neutral |
2018-09-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
2018-08-10 | Hochstufung | Citigroup | Neutral → Buy |
2018-03-23 | Hochstufung | Liberum | Hold → Buy |
2018-01-23 | Herabstufung | Barclays | Equal Weight → Underweight |
2017-12-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
2017-12-01 | Herabstufung | Morgan Stanley | Overweight → Underweight |
2017-11-15 | Hochstufung | Barclays | Underweight → Equal Weight |
2017-08-30 | Hochstufung | HSBC Securities | Reduce → Hold |
Alle ansehen
Sanofi Adr Aktie (SNY) Neueste Nachrichten
Weekly Upgrades and Downgrades - InvestorPlace
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease - Benzinga
Communiqué de presse - GlobeNewswire Inc.
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Sanofi Cancels Consumer Healthcare Business Spin-Off - Forbes
Here’s Why Mastercard Incorporated (NYSE: MA) Is An Attractive Investment Right Now - Stocks Register
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo Finance
16 New 4-Star Stocks - Morningstar
Sanofi SA (ADR: SNY) Stock Price Could Reach $63: Morningstar Research - TopNews India
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading - MSN
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat - Investor's Business Daily
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
Sanofi, HCA, Colgate-Palmolive lead Friday's earnings lineup By Investing.com - Investing.com Australia
Sanofi, HCA, Colgate-Palmolive lead Friday's earnings lineup - Investing.com
Sanofi Deal Jitters Imperil Stock’s Big Rebound - MSN
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale - Zacks Investment Research
Proactive news headlines: Ananda, Helix Exploration, Deltic, Light Science Technologies and more - Proactive Investors UK
French govt set to take stake in Sanofi unit after PE sale - Proactive Investors Australia
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Sanofi ADR: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Ratios Reveal: Breaking Down Sanofi ADR (SNY)’s Financial Health - The Dwinnex
EXK (Endeavour Silver Corp.) may reap gains as insiders became active recently - Knox Daily
Checking in on Clear Channel Outdoor Holdings Inc. (CCO) after recent insiders movement - Knox Daily
Investing in Sanofi ADR (SNY): What You Must Know - Knox Daily
Investing in Replimune Group Inc (REPL) Is Getting More Attractive - Knox Daily
An Analysis of KE Holdings Inc ADR (BEKE)’s Potential Price Growth - Knox Daily
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
OTC Drug and Dietary Supplement Market Opportunities and Strategies to 2033 - GlobeNewswire Inc.
Precidian to List First ADRhedged Securities in the U.S. on Cboe, Providing Exposure to Individual International Companies with an Embedded Currency Hedge - PR Newswire
Finanzdaten der Sanofi Adr-Aktie (SNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):